Patients Open to Non‑GLP‑1 Options

# Patients Open to Non‑GLP‑1 Options The obesity drug market has spent the last two years orbiting around one class of medicines: glucagon-like peptide-1 drugs, or GLP-1s. But a new patient survey from Phenomix Sciences suggests that the center of gravity may be less fixed than it looks. Among people who had already used obesity medication, many said they were not familiar with non-GLP-1 options. Once they learned those alternatives existed, a majority said their views changed. (prnewswire.com) That shift matters because obesity treatment is broader than the current public conversation. In the United States, federal health information lists six long-term prescription medicines for weight management, including older non-GLP-1 options such as orlistat, phentermine-topiramate, and naltrexone-bupropion, alongside GLP-1-based medicines such as liraglutide, semaglutide, and tirzepatide. The market may feel like a two-brand race today, but the approved toolbox is already wider than that. (niddk.nih.gov) Phenomix released the new findings on April 7, 2026, as part of its “2026 State of Obesity Treatment Report.” The company said the survey covered U.S. patients with overweight or obesity who had been treated with GLP-1 drugs, and it framed the results around a simple gap: treatment discussions remain heavily centered on GLP-1s even though many patients have limited awareness of alternatives. (prnewswire.com) The headline number is the awareness gap. Phenomix said 57% of surveyed patients were either completely unaware of, or unfamiliar with the details of, comparable non-GLP-1 weight-loss options such as Qsymia, the brand name for phentermine-topiramate. (prnewswire.com) The more interesting number came after patients were given more information. Phenomix said 68% changed their views on medications after learning about alternatives: 25% became more open to non-GLP-1 options, 25% said they would want to discuss all options with a healthcare provider, and 18% reported less interest in GLP-1s. (prnewswire.com) Those results do not prove patients will switch in large numbers. They do show that preference in obesity care is not just a matter of clinical efficacy or advertising reach. It is also shaped by what patients think exists, what tradeoffs they understand, and whether a clinician presents obesity treatment as a menu or as a single lane. That interpretation is consistent with recent clinical guidance emphasizing individualized, person-centered obesity care rather than one-size-fits-all prescribing. (prnewswire.com) That broader framing has been gaining support from major health bodies. On December 1, 2025, the World Health Organization released its first guideline on the use of GLP-1 medicines for obesity and described obesity as a chronic, relapsing disease that requires comprehensive and lifelong care. The guideline conditionally recommended GLP-1 therapies for some adults, but it also stressed limits around long-term evidence, cost, health-system readiness, and equity. (who.int) In other words, even the most prominent global endorsement of GLP-1s did not present them as a universal answer. The World Health Organization paired drug treatment with diet, physical activity, and professional support, which leaves room for multiple medication strategies depending on patient needs, tolerance, access, and risk profile. (who.int) That is where the commercial angle comes in. Investors have largely treated obesity pharmacotherapy as a race dominated by semaglutide and tirzepatide, the active ingredients in Wegovy and Zepbound. Both are approved by the Food and Drug Administration for chronic weight management in adults with obesity, or in adults with overweight plus at least one weight-related condition. (fda.gov) But if patient education can materially change willingness to consider other treatments, then market share may depend on more than headline weight-loss percentages. It may also depend on how companies and clinicians explain side effects, dosing, contraindications, insurance coverage, long-term use, and which patients are best suited to which therapy. Phenomix’s survey points to education itself as a competitive variable. (prnewswire.com) There is also a practical reason patients may want more than one path. Obesity affects more than 4 in 10 U.S. adults, according to the National Institute of Diabetes and Digestive and Kidney Diseases, and large populations rarely fit neatly into a single treatment model. Some patients respond well to newer injectables, some stop because of tolerability or cost, and others may prefer oral or older agents if the tradeoffs make more sense for them. (niddk.nih.gov) Phenomix has an obvious interest in promoting more personalized obesity care, so its survey should not be treated as neutral proof of an industrywide shift. Still, the findings fit a plausible pattern: when patients know only the most famous drugs, demand clusters around those drugs; when they learn there are other approved options, some of that demand spreads out. (prnewswire.com) For clinicians, the message is straightforward. A treatment discussion that starts and ends with GLP-1s may miss what some patients actually want once they understand the full set of choices. For investors, the takeaway is narrower but important: the obesity market may keep expanding without remaining as concentrated as current narratives suggest. (prnewswire.com)